Regeneron Pharmaceuticals (REGN) Operating Leases (2022 - 2025)
Regeneron Pharmaceuticals (REGN) posted quarterly Operating Leases of $986.8 million for Q4 2025, up 3.39% year-over-year from $954.4 million in Q4 2024, and up 3.39% quarter-over-quarter from $954.4 million in Q4 2024.
Regeneron Pharmaceuticals (REGN) Operating Leases (2022 - 2025) Analysis & Trends
Regeneron Pharmaceuticals' Operating Leases history runs 4 years deep, the most recent figure standing at $986.8 million for Q4 2025.
- In Q4 2025, Operating Leases rose 3.39% year-over-year to $986.8 million; the TTM figure through Dec 2025 stood at $986.8 million (up 3.39% YoY), while the FY2025 annual figure was $986.8 million, up 3.39% from the prior year.
- Operating Leases for Q4 2025 stood at $986.8 million, up from $954.4 million in the prior quarter.
- The five-year high for Operating Leases was $986.8 million in Q4 2025, with the low at $788.2 million in Q4 2022.
- The 4-year median for Operating Leases is $881.0 million (2023), against an average of $884.3 million.
- The sharpest annual moves came in 2023 and 2024: Operating Leases climbed 2.47% in 2023, then rose 18.16% in 2024.
- Regeneron Pharmaceuticals' Operating Leases stood at $788.2 million in 2022, then grew by 2.47% to $807.7 million in 2023, then grew by 18.16% to $954.4 million in 2024, then advanced by 3.39% to $986.8 million in 2025.
- Business Quant data shows REGN's Operating Leases at $986.8 million in Q4 2025, $954.4 million in Q4 2024, and $807.7 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 986.80 Mn |
| Dec 31, 2024 | 954.40 Mn |
| Dec 31, 2023 | 807.70 Mn |
| Dec 31, 2022 | 788.20 Mn |